Portal CEO on Lilly Deal for Cancer Biotech CrossBridge

Portal Innovations CEO John Flavin provides a look into the 2026 biotech M&A pipeline and breaks down Eli Lilly’s purported acquisition of CrossBridge Bio for up to $300 million, bolstering its oncology segment. He talks with Katie Greifeld and Romaine Bostick on “The Close.” (Source: Bloomberg)

Source

Bloomberg Markets

Read full article at Bloomberg Markets

Opens original article in a new tab

The S&P 500 just clinched a record high. Here are 6 charts to watch for what comes next.

The index on Wednesday tallied its first intraday and closing record highs since the start of the Iran conflict.

about 2 hours agoRead more →

EconomyDaily Composite

CNBC

Ford EV chief leaving automaker amid new restructuring efforts

The departure was announced alongside Ford detailing a new restructuring that includes the establishment of a "Product Creation and Industrialization" unit.

about 2 hours agoRead more →

EconomyDaily Composite

CNBC

Goldman Sachs bond traders stumbled as Wall Street rivals thrived: 'A fire is being lit under' them

Goldman's identity as a trader's firm — one expected to perform in turbulent markets — makes any stumble in the division notable.

about 2 hours agoRead more →

MarketWatch

‘I’m in my 30s and majored in finance’: In the age of AI, which pays off — a CFA or an executive MBA?

“I want long-term job security and to not be in a crazy amount of debt.”

about 2 hours agoRead more →

Related Economy Stories

The S&P 500 just clinched a record high. Here are 6 charts to watch for what comes next.

Ford EV chief leaving automaker amid new restructuring efforts

Goldman Sachs bond traders stumbled as Wall Street rivals thrived: 'A fire is being lit under' them

‘I’m in my 30s and majored in finance’: In the age of AI, which pays off — a CFA or an executive MBA?